Donate
Georgia Cannabis Policy Guide 2026
By Georgia Medical Cannabis Society (GMCS) · Georgia GreenScapes
From Haleigh's Hope to the "Putting Georgia's Patients First Act" — SB 220 has passed… now the real work begins. Use the navigation below to jump to any section.
👇 Navigate the Guide
Executive Summary
Executive Summary
SB 220 marks a shift toward a structured medical cannabis program in Georgia. Progress has been made… but access is still limited.
🏛️ A Structured Program
SB 220 establishes clearer rules, expanded conditions, and a milligram dosing system — moving Georgia toward a more formalized medical cannabis framework.
✅ Progress Made
Plant material and vaporization are now permitted for registered patients 21 and older. Licensed dispensaries provide legal access points across the state.
⚠️ Access Still Limited
Despite legislative advances, significant barriers remain for patients — including housing concerns, use restrictions, and gaps in provider availability.
Key Update
SB 220 — "Putting Georgia's Patients First Act"
Where Things Stand
SB 220 has passed both chambers of the Georgia General Assembly. The bill is now awaiting final outcome at the Governor level.
This represents the most significant advancement in Georgia's medical cannabis policy in years — expanding access, formalizing oversight, and introducing new delivery methods for registered patients.
What the Bill Does
  • Allows plant material (vaporization only, 21+)
  • Introduces a milligram dosing system
  • Expands qualifying conditions
  • Strengthens program oversight
  • Requires Georgia-based physician involvement

Federal Update · April 2026
A Historic Shift: Federal Cannabis Rescheduled to Schedule III
The Official Order — What It Says
On April 22, 2026, Acting Attorney General Todd Blanche issued a Final Order under 21 U.S.C. §811(d)(1) placing state-licensed medical cannabis and FDA-approved cannabis products into Schedule III of the Controlled Substances Act. This action was taken to fulfill U.S. obligations under the United Nations Single Convention on Narcotic Drugs (1961) — the treaty framework that has governed cannabis scheduling since 1970.
The legal authority: Section 811(d)(1) of the CSA allows the Attorney General to schedule a substance "without regard to" the normal HHS findings or rulemaking procedures when required by international treaty obligations.
Key Provisions of the Final Order
  • State-licensed medical cannabis moves from Schedule I → Schedule III (effective April 22, 2026)
  • FDA-approved cannabis drug products also rescheduled to Schedule III
  • Unlicensed/recreational cannabis remains Schedule I
  • Synthetic THC remains Schedule I
  • Section 280E tax burden lifted — state licensees no longer subject to trafficking tax disallowance
  • DEA expedited registration process established for state licensees (60-day application window)
  • State medical marijuana certifications accepted in lieu of federal prescriptions
  • State security, labeling, and disposal rules accepted in lieu of federal requirements
  • DEA expedited hearing set for June 29, 2026 on broader rescheduling
What This Means for Georgia
Georgia's SB 220 program — which operates under a state medical marijuana license — now functions in a dramatically improved federal environment. Georgia-licensed operators may now apply for DEA Schedule III registration, are no longer subject to Section 280E tax penalties, and can engage in federally compliant medical cannabis activity. This is the direct result of 54 years of legal battles beginning with NORML's 1972 petition.
Source: U.S. Department of Justice / DEA Final Order, Effective April 22, 2026. Signed by Acting Attorney General Todd Blanche. Docket: DEA Final Order under 21 U.S.C. §811(d)(1).
What Is Legal
Legal Access Under Georgia's Medical Cannabis Program
What Registered Patients Can Access
  • Registered patient access through the state program
  • Up to 12,000 mg THC (via milligram dosing system)
  • Licensed dispensaries as legal purchase points
  • Vaporization of plant material (patients 21+)
How to Access Legally
Patients must be registered with Georgia's medical cannabis program through a qualifying Georgia-based physician. Once registered, they may purchase from licensed dispensaries and use cannabis via approved methods within the limits set by SB 220.
What Is Not Legal
Prohibited Activities Under Georgia Law
Even with the passage of SB 220, significant restrictions remain. The following are not permitted under Georgia's medical cannabis program:
🚫 Smoking
Combustion-based smoking of cannabis remains prohibited. Only vaporization of plant material is permitted for eligible registered patients.
🚫 Edibles
Cannabis-infused food and beverage products (edibles) are not authorized under the current Georgia medical cannabis framework.
🚫 Public Consumption
Consuming cannabis in public spaces is not permitted, regardless of registration status. Use is restricted to private settings.
🚫 Unregistered Possession
Possessing cannabis without being a registered patient in the state program remains a violation of Georgia state law.
Quick Reference
At-a-Glance: What Doctors & Patients Need to Know
Doctors / Physicians
  • Must be licensed in Georgia and registered with GMCS.
  • Certify patients with qualifying conditions.
  • Check PDMP (Prescription Drug Monitoring Program) before certifying.
  • Issue Low THC Oil Registry Card certifications.
  • Report patient data as required by law.
  • Cannot certify themselves or immediate family.
  • Renewal certifications required annually.
  • SB 395: Must complete cannabis education CME.
Patients
  • Must have a qualifying medical condition.
  • Obtain physician certification.
  • Register with Georgia's Low THC Oil Registry.
  • Carry registry card at all times.
  • Purchase only from licensed dispensaries (Class 1 or Class 2).
  • Possession limit: up to 20 fluid oz of low THC oil.
  • No smoking or public consumption.
  • Card must be renewed annually.

⚖️ Federal Schedule III — What It Means for Georgia Patients & Providers

Effective April 22, 2026 — cannabis rescheduled from Schedule I → Schedule III by DEA Final Order Section 280E tax burden lifted — state-licensed operators no longer subject to federal trafficking tax disallowance DEA expedited registration open — 60-day application window, processed within 6 months State medical cannabis certifications accepted in lieu of federal prescriptions State security, labeling, and disposal rules accepted federally Georgia's SB 220 program is directly covered — operators immediately eligible for DEA Schedule III registration Unlicensed and recreational cannabis remains Schedule I — no change DEA broader rescheduling hearing set for June 29, 2026 Source: DOJ Final Order, April 22, 2026 · justice.gov/opa/media/1437441/dl Read Full DOJ Final Order →

For full program details visit georgiamcs.org
What Changed
SB 220 — Key Provisions
Plant Material Allowed
For the first time, plant material is permitted — but only via vaporization, and only for patients 21 and older.
Milligram Dosing System
A structured milligram dosing system is introduced, bringing precision and accountability to patient access and dispensary operations.
Expanded Conditions
The list of qualifying medical conditions is expanded, allowing more Georgia patients to access the program legally.
Stronger Oversight
Enhanced compliance requirements and reporting obligations are established to ensure program integrity and patient safety.
Before vs. After: 2025 → 2026
SB 220 represents a meaningful shift in what Georgia's medical cannabis program permits. Here's how the landscape changed:
Provider Requirements
What Georgia Physicians Must Do Under SB 220 & SB 395 — As Passed 2026
Under SB 220 and SB 395, physicians are responsible for certifying eligible patients, checking required records, reporting outcomes to support oversight and research, and complying with updated data-disclosure rules.
Georgia-Licensed Physicians Only
Only physicians licensed in Georgia and whose principal place of practice is located in Georgia may certify patients. Out-of-state physicians are not accepted. The physician must have an established doctor-patient relationship and must be actively treating the patient for the specific qualifying condition, or treating the patient in a hospice program.
Check Prescription Drug Monitoring Database
Before certifying any patient, the physician must seek and review information about that patient from the prescription drug monitoring program database established under Code Section 16-13-57. This review must happen before the patient is certified to the Department of Public Health.
Certify Patients to the Department of Public Health
Physicians certify eligible patients to the Georgia Department of Public Health as having a qualifying condition, or as being enrolled in a hospice program, and authorize them to use medical cannabis as treatment. The board establishes uniform procedures and rules for certification.
Annual Reporting to the Georgia Composite Medical Board
Physicians must submit reports once per year to the Georgia Composite Medical Board. The reports must include dosages recommended for each condition, patient clinical responses, levels of THC or THCA in test results, patient compliance, responses to treatment, side effects, and drug interactions. These reports are used for research to determine the efficacy of medical cannabis as a treatment. A physician's failure to submit such a report shall not serve as the basis for the department to cancel or revoke a patient's registration card.
Annual Condition Review Participation
The Georgia Composite Medical Board, in coordination with the Department of Public Health, reviews qualifying conditions annually and recommends additions based on medical research. Recommendations — including dosages, patient responses, and drug interactions — must be submitted to the General Assembly no later than December 1 each year.
Patient Registry Data & Board Oversight
Under SB 395, patient registry information may also be disclosed by the Department of Public Health to the Georgia Composite Medical Board for investigatory, compliance, or disciplinary purposes, in addition to existing disclosures to patients, law enforcement, and research entities.
Patient Reality
The Lived Reality of Georgia Medical Cannabis Patients
What SB 220 Changes for Patients
SB 220 expands qualifying conditions, renames the program “Medical Cannabis,” allows vaporization for patients 21+, raises possession to 12,000mg THC, extends cards to 5 years, and permits electronic cards for immediate access. Patients with incurable or irreversible conditions are no longer required to recertify annually.
The Housing Gap — A Practical Prohibition
Even with a valid registration card, a patient’s housing situation can determine whether they have any lawful place to use medicine. For many Georgians, access depends on where they live.
Who Faces Housing Barriers in Georgia
~1.4 Million Renter Households
Georgia’s homeownership rate is 65.4%, leaving roughly 1 in 3 households renting. Many lease terms restrict federally illegal substances.
258,000 Georgians in Subsidized Housing
HUD guidance says federal housing providers are not required to accommodate medical cannabis use, which can leave residents without a lawful option.
108,000+ in Congregate Care
Assisted living, senior housing, and nursing homes all operate under rules that may limit how residents use treatment.
Disproportionate Impact
Older adults, people with disabilities, and economically vulnerable patients are most likely to live in regulated housing and qualify under SB 220.


Georgia Housing Landscape — Who May Lack a Lawful Place to Use Medicine
~34.6% of Georgia households face potential housing barriers to medical cannabis access. Source: ASA, February 2026
“Cannabis medicines provide relief to millions of Americans, often serving as a crucial alternative when conventional treatments have failed or as a safer option compared to pharmaceuticals.” — Americans for Safe Access, February 2026
Research credit: Americans for Safe Access (ASA) — GMCS National Affiliate | www.SafeAccessNow.org
Definitions
Key Terms in Georgia Cannabis Policy
Cannabis (Cannabis sativa L.)
The plant species from which both hemp and medical cannabis are derived. In Georgia, cannabis is regulated differently depending on its THC content and intended use.
Hemp (≤0.3% THC)
Cannabis plants containing 0.3% THC or less by dry weight. Hemp is federally legal under the 2018 Farm Bill and is used for fiber, CBD products, and other industrial purposes.
Medical Cannabis
Cannabis products authorized for use by registered patients under Georgia's medical cannabis program, including low-THC oil and, under SB 220, vaporizable plant material.
Decriminalization vs. Legalization
Decriminalization reduces or eliminates criminal penalties for possession without making cannabis fully legal. Legalization creates a regulated, legal market. Georgia has elements of both — local decriminalization in some cities, and a state-level medical program — but has not legalized cannabis broadly.
Timeline Introduction
Georgia's Cannabis Policy Didn't Happen Overnight
A 54-year journey — from federal prohibition in 1970 to the historic DEA Final Order on April 22, 2026. Shaped by patietients,ntntntnts, advocates, courts, and legislators who refused to give up.
1970–1979 — Federal Foundations
CSA enacted · NORML founded · First rescheduling petition filed
1980–1994 — The Hearing Years
Judge Young rules · DEA overrules · Federal reform stalls
2015–2019 — Georgia Awakens
Haleigh's Hope Act · Georgia's Hope Act (HB 324) · GMCS established
2025–2026 — Georgia Reform Era
SB 220 passes both chambers · Awaiting Governor's signature
April 22, 2026 — Federal Historic Shift
Cannabis rescheduled Schedule I → Schedule III by DEA Final Order
Why This Matters for Georgia Right Now
Georgia's SB 220 program operates under a state medical marijuana license — placing it squarely within the April 22, 2026 federal order. Immediate benefits for Georgia operators and patients:
  • Eligible for DEA Schedule III registration (60-day window open now)
  • No longer subject to Section 280E federal tax penalties
  • State certifications accepted in lieu of federal prescriptions
  • State security and labeling rules accepted federally
  • DEA broader rescheduling hearing: June 29, 2026
Key Dates at a Glance
  • 1970 — CSA enacted, cannabis placed in Schedule I
  • 1972 — NORML files first rescheduling petition
  • 1974 — Court of Appeals orders DEA to hold hearings
  • 1978 — FDA holds public hearings, no action taken
  • 1985 — FDA approves Marinol (synthetic THC)
  • 1988 — Judge Young rules marijuana misclassified
  • 1989 — DEA administrator overrules Judge Young
  • 1994 — Final court ruling ends federal effort
  • 2015 — Georgia's Haleigh's Hope Act signed
  • 2019 — Georgia's Hope Act expands access
  • 2025 — SB 220 introduced in Georgia
  • April 22, 2026 — Federal rescheduling to Schedule III
From NORML's first petition in 1972 to Judge Young's landmark 1988 ruling, through Georgia's Haleigh's Hope Act in 2015, SB 220 in 2026, and the federal rescheduling to Schedule III on April 22, 2026 — this timeline connects every dot in one of the longest and most consequential policy battles in American history.
Sources: U.S. Dept. of Justice / DEA Final Order (April 22, 2026) · DEA.gov · NORML.org · Georgia General Assembly (legis.ga.gov) · Alice O'Leary Randall & Project 50 (aliceolearyrandall.com/research) · Judge Young DEA Docket No. 86-22
Timeline · 1970–1979
The Federal Foundation: Scheduling, NORML & Early Battles
1970 — Controlled Substances Act & NORML Founded
The Controlled Substances Act (CSA) becomes law, establishing the federal drug scheduling system. Cannabis is placed in Schedule I. NORML is founded by Keith Stroup and Larry Schott to advocate for reform.
1972 — NORML Petitions for Rescheduling (March)
NORML files a petition with federal drug agencies to remove marijuana from Schedule I based on medical use. The petition is rejected without hearings. NORML files with the U.S. Court of Appeals (COA) — see NORML v. Ingersoll, 497 F.2d 654 (D.C. Cir. 1974). Georgia also passes the Controlled Substances Therapeutic Research Act, acknowledging potential medical value.
1972 / 2009 — Georgia's Controlled Substances Therapeutic Research Act (§ 43-34-120 & § 43-34-121)
Georgia's Controlled Substances Therapeutic Research Act established the legal framework for physician-supervised cannabis research for cancer and glaucoma patients. The legislative intent (§ 43-34-121) recognized marijuana's potential therapeutic value — including relief of chemotherapy-related nausea and reduction of intraocular pressure in glaucoma patients — while limiting use to clinical trials. The act was amended in 2009 (Ga. Laws 243, § 1).
1974 — Court of Appeals Orders Hearings (June)
The COA orders the DEA's predecessor, BNDD, to hold public hearings, stating its delay "is not the kind of Agency action that promotes refinement of views that is the lifeblood of administrative process." Read the ruling: NORML v. Ingersoll, 497 F.2d 654 (D.C. Cir. 1974) →
1975 — DEA Denies Petition Again (May)
The DEA administrator denies NORML's petition with no hearings, but does accept that rescheduling would be compliant with U.S. Treaty obligations.
1977 — COA Remands for a 2nd Time (September)
The COA remands the petition to the agencies for a second time. Thirteen citizen petitions are incorporated into the NORML petition, setting the stage for the Alliance for Cannabis Therapeutics. Read the ruling: NORML v. DEA, 559 F.2d 735 (D.C. Cir. 1977) →
1978 — FDA Holds Public Hearings (January)
FDA holds public hearings before the Controlled Substances Advisory Committee, which votes to reschedule THC and CBD — but not marijuana. Nothing further happens for a year.
1979 — NORML Returns to COA (September)
NORML returns to the COA charging unreasonable delay. DHEW sends its evaluation to DEA on June 4th. Ten days later, DEA publishes a rejection of the petition. NORML returns to the COA.
These federal battles set the legal and political context for all state-level cannabis policy, including Georgia's.
Source & Credit: Alice O'Leary Randall & Project 50 — aliceolearyrandall.com/research | NORML History of Rescheduling Petitions — norml.org | DEA Controlled Substances Act — dea.gov/drug-policy-information | GA Code § 43-34-120 & § 43-34-121 (Justia Law) — law.justia.com
Timeline · 1980–1994
The Hearing Years: Courts, Congress & Continued Delay
1980 — Court Refuses to Limit Hearings (April)
The government asks the court to limit hearings to synthetic THC only. The COA refuses and, for a third time, orders proper hearings and procedure on the reclassification petitions.
1982 — Agencies Drag Their Feet (October)
The agencies delay for 18 months. FDA is initially inclined to reschedule only THC while publicly admitting that THC and marijuana are the same. It concludes THC can only be rescheduled if approved for marketing.
1985 — FDA Approves Dronabinol (Marinol)
FDA approves synthetic THC for marketing as dronabinol under the brand name Marinol — a significant but narrow step. FDA NDA 018651 — Approved May 31, 1985 →
1986 — DEA Reschedules Synthetic THC; Hearings Announced
The DEA reschedules synthetic THC to Schedule II of the CSA. In May, the DEA administrator publishes a notice of public hearings on the long-standing NORML petition. DEA Docket No. 86-22
1987 — First Hearings Held
The first hearings before DEA administrative law judge Francis Young are held in New Orleans and San Francisco.
1988 — Judge Young Rules: Marijuana Misclassified
Hearings conclude in Washington, DC in February. Oral arguments are held in June. In September, Judge Young concludes marijuana is mis-classified in Schedule I — a landmark finding. Read the full ruling →
1989 — DEA Rejects Judge Young's Decision
The DEA administrator rejects Judge Young's decision, claiming proponents "have attempted to perpetrate a dangerous and cruel hoax on the American public."
1990–1992 — Continued Court Battles
ACT and NORML return to the COA several times, asking that the DEA's rejection of its ALJ ruling be reversed.
1994 — Final Court Ruling Ends Federal Rescheduling Effort
The U.S. Court of Appeals rules that a DEA administrator has the final word in rescheduling matters. It is the final blow in the longest-running effort to reschedule cannabis at the federal level. Read the ruling: Alliance for Cannabis Therapeutics v. DEA, 15 F.3d 1131 (D.C. Cir. 1994) →
While federal reform stastallestastallellelled, states like Georgia began charting their own course — starting with Haleigh's Hope Act in 2015.
Sources: Alice O'Leary Randall & Project 50 (aliceolearyrandall.com/research) | NORML (norml.org) | DEA Drug Policy (dea.gov/drug-policy-information) | Judge Young's Full Ruling, DEA Docket No. 86-22 | Alliance for Cannabis Therapeutics v. DEA, 15 F.3d 1131 (D.C. Cir. 1994) — law.justia.com | FDA NDA 018651 (accessdata.fda.gov)
Timeline · 2016–2019
Local Decriminalization & Georgia's Hope Act
With federal rescheduling efforts exhausted by 1994, Georgia began its own path — starting with Haleigh's Hope Act in 2015 and expanding through local decriminalization efforts.
2016 — Local Decriminalization Begins
Cities across Georgia begin reducing penalties for cannabis possession at the local level. Atlanta, Athens, Savannah, and others lead the way — though these measures do not override state law.
2019 — Georgia's Hope Act
A legal supply chain is introduced for the first time. Georgia's Hope Act allows licensed dispensaries to cultivate and dispense low-THC oil, giving registered patients a legal, in-state source for their medicine.
Timeline · 2025–2026
SB 220 & The Road to Reform
2025 — SB 220 Introduced
SB 220, the "Putting Georgia's Patients First Act," is introduced in the Georgia General Assembly, proposing significant expansions to the state's medical cannabis
2025 — Blue Ribbon Study Committee
A Blue Ribbon Study Committee is convened to examine Georgia's cannabis policy landscape. GMCS is invited to present, providing expert testimony on vaporization and medical devices.
2026 — SB 220 Finalized with Vaporization
SB 220 passes both chambers with vaporization included as a permitted delivery method for registered patients 21 and older — a direct result of advocacy and education efforts.
April 22, 2026 — Federal Rescheduling: Schedule I → Schedule III
Acting Attorney General Todd Blanche signs the DEA Final Order rescheduling state-licensed medical cannabis to Schedule III of the Controlled Substances Act — effective immediately. Georgia's SB 220 program, operating under a state medical marijuana license, is directly covered by this order. The 54-year federal battle that began with NORML's 1972 petition reaches a historic milestone. Read the full order →
Policy Access Growth: 1980 → 2026
Georgia's medical cannabis access has expanded incrementally over four decades, with the most significant legislative leaps occurring in 2015, 2019, and 2026.
Each legislative milestone — from the 1980 Research Act to SB 220 — represents a measurable expansion of patient access and program structure in Georgia.
What the scores mean: The Policy Score (1–10) reflects the relative level of patient access and program structure at each milestone — from early research (1) to full dispensary access with vaporization (10).
Local Policy
Local Decriminalization Across Georgia
A growing number of Georgia cities have taken steps to reduce penalties for cannabis possession at the local level. These include Atlanta, Athens, Savannah, and others.
Cities Reducing Penalties
Atlanta, Athens, Savannah, and other municipalities have passed local ordinances reducing fines and eliminating arrest for small amounts of cannabis possession.
State Law Still Applies
Local decriminalization is a policy choice by city governments — it does not change Georgia state law. State law enforcement retains authority to enforce state statutes.
Data & Reporting
Program Accountability Through Data
Georgia's medical cannabis program relies on robust data collection and reporting to ensure patient safety, regulatory compliance, and long-term program integrity.
Patient Tracking
The state maintains a registry of all registered medical cannabis patients, enabling accurate tracking of program participation and patient demographics across Georgia.
Compliance Oversight
Licensed dispensaries and cultivators are subject to ongoing compliance monitoring, including inventory tracking, sales reporting, and regular inspections by state regulators.
Program Accountability
Aggregate data on patient outcomes, dispensary operations, and physician participation is used to evaluate program effectiveness and inform future legislative decisions.
Blog
Latest Insights & Articles
Stay informed with our latest analyses, policy updates, and patient stories from the Georgia cannabis community.
Navigating Georgia's New Cannabis Laws
April 20, 2026 · By GMCS Policy Team
A deep dive into the implications of SB 220 and SB 395 for patients and providers as federal rescheduling takes effect.
Patient Voices: Stories from the Front Lines
April 15, 2026 · By GMCS Patient Advocacy Team
Hear firsthand accounts from Georgia patients on how medical cannabis has impacted their lives and the challenges they still face.
The Future of Cannabis in Georgia: Beyond 2026
April 10, 2026 · By GMCS Research Team
Explore predictions and potential legislative changes that could shape the state's cannabis landscape in the coming years.
Collaboration
Partners in Compassion
Our mission to expand equitable access to medical cannabis is strengthened through strategic partnerships with organizations that share our commitment to patient well-being and health equity.
Healthcare Providers
Physicians, clinics, and hospitals integrating medical cannabis education and patient navigation into mainstream care.
Advocacy Groups
State and national advocacy organizations championing patient rights, policy reform, and underserved communities.
Research Institutions
Academic and research bodies gathering evidence and analyzing patient outcomes to advance the science.
Nonprofits & Community Groups
Local nonprofits, faith-based organizations, and support networks delivering on-the-ground education and compassionate care.
Schools & Universities
Educational institutions helping train the next generation of informed providers, advocates, and policymakers.
Government & Civic Bodies
Municipal and state agencies working to align policy with patient needs and public health goals.
🤝 Become a Partner in Compassion
Ready to join us? Fill out our partnership inquiry form and a member of our team will follow up within 48 hours. Whether you're looking to host a workshop, collaborate on research, co-sponsor an event, or simply learn more — we'd love to connect.
📬 Contact Us Directly
  • General inquiries: info@georgiamcs.org
  • Education & workshops: info@georgiamcs.org
  • Partnerships: partnerships@georgiamcs.org
  • Media & podcast: media@georgiamcs.org
📍 Find Us
GMCS hosts in-person and virtual events across Georgia. Visit georgiamcs.org for the latest schedule, upcoming Lunch & Learns, Masterclasses, and community events.
What Comes Next
Building a System That Truly Serves Patients
Expansion of Conditions
Continued advocacy to expand the list of qualifying medical conditions, ensuring more Georgia patients can access the program legally.
Homegrow Consideration
Exploring the possibility of allowing registered patients to cultivate a limited number of plants at home — a measure that could dramatically improve access for underserved communities.
Better Patient Protections
Strengthening legal protections for registered patients in housing, employment, and public life — so that having a medical cannabis card doesn't come with undue consequences.
Georgia has taken a step forward… now the focus is building a system that truly serves patients.
Georgia Medical Cannabis Society Patients Over Profits… Always www.georgiamcs.org
Blog · Policy Update
Navigating Georgia's New Cannabis Laws
April 20, 2026 · By GMCS Policy Team · 6 min read
The passage of SB 220 and SB 395, combined with the federal rescheduling of cannabis to Schedule III on April 22, 2026, marks the most significant shift in Georgia's medical cannabis landscape since Haleigh's Hope Act in 2015. Here's what patients, providers, and advocates need to know right now.
What SB 220 Actually Does
SB 220 — officially titled the 'Putting Georgia's Patients First Act' — passed both chambers of the Georgia General Assembly in 2025 and is now awaiting the Governor's signature. The bill represents a major expansion of Georgia's medical cannabis program in several key areas:
Plant Material Allowed
For the first time, Georgia patients 21 and older may access cannabis plant material for vaporization — not just low-THC oil. This is a landmark shift from the oil-only framework that has governed the program since 2015.
Milligram Dosing System
SB 220 introduces a milligram-based dosing framework, giving physicians and patients clearer, more precise guidance on THC and CBD amounts — moving away from the fluid ounce measurement system.
Expanded Qualifying Conditions
The bill expands the list of qualifying medical conditions, making the program accessible to more Georgians who could benefit from medical cannabis treatment.
Stronger GMCS Oversight
The Georgia Medical Cannabis Commission receives enhanced oversight authority, including new licensing frameworks and compliance requirements for dispensaries and producers.
What SB 395 Adds
Running alongside SB 220, SB 395 adds important physician accountability measures: doctors must now complete cannabis-specific continuing medical education (CME), conduct PDMP (Prescription Drug Monitoring Program) checks before certifying patients, and submit detailed patient outcome reports to GMCS. These requirements are designed to ensure that certifications are medically grounded and that the program maintains integrity.
The Federal Layer: Schedule III Changes Everything
On April 22, 2026, Acting Attorney General Todd Blanche signed the DEA Final Order moving state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act. For Georgia operators and patients, this means:
  • Section 280E no longer applies — Georgia cannabis businesses can now deduct ordinary business expenses on federal taxes
  • DEA registration is now available — a 60-day application window is open for Georgia-licensed operators
  • State certifications are accepted federally — no separate federal prescription required
  • State security and labeling standards are accepted at the federal level
  • Recreational and unlicensed cannabis remains Schedule I
What This Means for Patients Right Now
If you are a current registered patient in Georgia's Low THC Oil Registry, your card remains valid. Once SB 220 is signed by the Governor, you may be eligible to access plant material (vaporization only) through licensed dispensaries. Watch for updates from GMCS on implementation timelines and any re-registration requirements.
Sources: Georgia General Assembly · DEA.gov · DOJ Final Order April 22, 2026 · GMCS (gmcc.georgia.gov)
Blog · Patient Stories
Patient Voices: Stories from the Front Lines
April 15, 2026 · By GMCS Patient Advocacy Team · 7 min read
Behind every policy change is a person. A parent. A veteran. A cancer survivor. A child with epilepsy. Georgia's medical cannabis program exists because real people fought for it — and continue to fight every day. Here are their stories.
Haleigh's Story — Where It All Began
Georgia's medical cannabis journey began with a little girl named Haleigh Cox. Diagnosed with a severe form of epilepsy called Dravet syndrome, Haleigh experienced hundreds of seizures per week. Her parents, Brian and Janea Cox, became fierce advocates after learning that cannabis oil had helped children like Haleigh in other states. Their advocacy — alongside families across Georgia — led directly to the Haleigh's Hope Act of 2015, which legalized low-THC cannabis oil for a narrow set of qualifying conditions. Haleigh's story is a reminder that policy is personal.
Veterans Finding Relief
Georgia is home to hundreds of thousands of veterans, many of whom live with PTSD, chronic pain, and traumatic brain injuries. For years, veterans told GMCS that they were turning to cannabis — legally in other states, or illegally in Georgia — because it was the only thing that helped them sleep, manage pain, or quiet the noise of combat trauma. SB 220's expansion of qualifying conditions and the federal Schedule III rescheduling represent a turning point for Georgia's veteran community. DEA registration means that VA-adjacent providers may now be able to engage with the program in ways previously impossible.
Cancer Patients and the Oil-Only Barrier
Under Georgia's previous framework, patients could only access low-THC cannabis oil — a significant limitation for cancer patients who needed higher doses or different delivery methods to manage nausea, pain, and appetite loss during chemotherapy. SB 220's introduction of plant material (vaporization only, for patients 21+) and a milligram dosing system gives oncologists and patients more precise, flexible tools. 'It's not perfect,' one patient advocate told GMCS, 'but it's a real step forward.'
The Caregiver Burden
For many Georgia patients — especially children and elderly individuals — the burden of the program falls on caregivers. Driving hours to a licensed dispensary, navigating complex registration requirements, and managing annual renewals while also caring for a loved one is exhausting. GMCS continues to advocate for expanded dispensary access, telehealth certification options, and streamlined renewal processes to reduce the caregiver burden.
Sources: GMCS Patient Advocacy Program · Georgia General Assembly · Haleigh's Hope Act (2015) · SB 220 (2025)
Blog · Future Outlook
The Future of Cannabis in Georgia: Beyond 2026
April 10, 2026 · By GMCS Research Team · 8 min read
With SB 220 passed, SB 395 enacted, and cannabis rescheduled federally to Schedule III, Georgia stands at a historic inflection point. But what comes next? GMCS looks ahead at the legislative, regulatory, and cultural shifts that could define Georgia's cannabis landscape through 2030 and beyond.
The DEA Broader Rescheduling Hearing — June 29, 2026
The April 22, 2026 DEA Final Order was a targeted action — covering only state-licensed medical cannabis and FDA-approved cannabis drug products. But a broader rescheduling hearing is already scheduled for June 29, 2026. This hearing could expand Schedule III coverage, address synthetic THC, and potentially open the door to broader federal reform. Georgia advocates and operators should be watching closely and submitting public comments.
What Full Legalization Could Look Like in Georgia
Georgia remains one of the more conservative states on cannabis policy, but the political landscape is shifting. A 2025 poll found that over 70% of Georgians support medical cannabis access, and a growing number support broader decriminalization. While full adult-use legalization is not on the immediate horizon, GMCS anticipates continued expansion of qualifying conditions, increased dispensary licenses, and potential homegrow provisions for registered patients in the next 2–3 legislative sessions.
Economic Opportunity and Equity
Georgia's cannabis industry is still in its early stages, but the economic potential is significant. With Schedule III registration now available, Georgia-licensed operators can access banking services, deduct business expenses, and attract investment in ways previously impossible. GMCS is committed to ensuring that this economic growth includes communities most harmed by the War on Drugs — through equity licensing provisions, expungement advocacy, and workforce development programs.
The Role of Education
One of the biggest barriers to Georgia's program reaching its full potential is education — for patients, providers, and the public. Too many Georgians don't know they qualify. Too many physicians are hesitant to certify. Too many employers still have outdated cannabis policies. GMCS's Lunch & Learn series, Masterclasses, and podcast are designed to close these gaps — one conversation at a time.
What GMCS Is Watching
01
Governor's Signature on SB 220
The final step before SB 220 becomes law. Implementation timelines and GMCS rulemaking will follow.
02
DEA Hearing — June 29, 2026
Could expand Schedule III coverage and signal the direction of broader federal reform.
03
GMCS Rulemaking
The Georgia Medical Cannabis Commission will issue new rules on plant material, dosing, and dispensary operations.
04
2027 Legislative Session
Watch for bills on homegrow, condition expansion, equity licensing, and potential decriminalization measures.
Sources: DEA Final Order April 22, 2026 · Georgia General Assembly · GMCS Policy Research · DOJ Office of Public Affairs